The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

URGENT BC Patient and Caregiver Input Request: Vosevi

URGENT BC Patient and Caregiver Input Request: We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Check out the background information in links below to see the results that have been achieved in clinical trials to date. Gilead’s “SOF-VEL-VOX” combo is pan-genotypic (works for all genotypes). One pill

Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6

URGENT BC Patient and Caregiver Input Request: We need to hear your voice! Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6.  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes).  Check out the background information in links below to learn the results that have been achieved in clinical trials to date. You will see that the cure rates across all genotypes are hig

Hepatitis B (HBV) Patients & Caregivers – Your Help Requested re Vemlidy

Do you have HEPATITIS B or are you a CAREGIVER for someone with HBV? This is really important for you! An improved hepatitis B treatment will likely be available to Canadians soon, but first the federal government has requested us to submit a patient group review to them (CADTH) explaining whether hepatitis B patients want this new treatment, and why. What is the new hepatitis B treatment? It is tenofovir alafenamide or TAF (brand name VemlidyTM) made by

Patient Input Is Requested by CADTH on Gilead’s “pan-genotypic” combo of sofosbuvir+velpatasvir+voxilaprevir (brand name “Vosevi”) for re-treatment of patients with hepatitis C, genotypes 1-6

YOUR HELP IS URGENTLY NEEDED! (Canadians and Non-Canadians Welcome to Participate). Input Needed Before August 15, 2017. Did you or someone you love fail treatment with one of the new interferon-free “DAAs”? Worried about “treatment-resistant” hepatitis C viruses developing? Here’s a new treatment that could help solve these problems. If you are a patient (current or former) or caregiver with an opinion on whether a treatment like this should (or shouldn’

Patient and Caregiver input is requested by CADTH on AbbVie’s combo of glecaprevir and pibrentasvir (G/P)

URGENT!  Patient and Caregiver Input Request: We Need to Hear your Voice! Patient and Caregiver input is requested by CADTH on AbbVie’s BRAND NEW (not yet for sale in Canada!) combo of glecaprevir and pibrentasvir (G/P) for Genotypes 1-6.  AbbVie’s G/P combo is pan-genotypic (works for all genotypes).  Check out the background information in links below to see the results that have been achieved in clinical trials to date. You will see that the cure rates

Pan-Genotypic Hep C Drug Epclusa™ Recommended for PharmaCare Coverage by CADTH

Epclusa™, a Direct-Acting-Antiviral combo for ALL GENOTYPES of Chronic Hepatitis C, received approval from CADTH on October 28, 2016. This combo of (generics) sofosbuvir and velpatasvir, from Gilead Sciences, was recommended by CADTH's Canadian Drug Expert Committtee (CDEC) for reimbursement by provincial and territorial PharmaCares... "if the following CRITERION and CONDITION are met: (1) CONDITION: "Reduce the price." CDEC noted that the cost of t

REQUEST FOR PATIENT and CAREGIVER INPUT: Gilead’s EPCLUSA

A Hep C treatment option for ALL genotypes? What do YOU think about this? Hello!  Once again, HepCBC is calling for your input.  BC PharmaCare is reviewing whether to add another Direct Acting-Antiviral (DAA) for hepatitis C to its formulary (list of drugs it will cover) Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir and velpatasvir for Genotypes 1-6 (brand name: Epclusa®).  Gilead’s combo is the first pan-gen

Patient Input Is Requested by CADTH on Gilead’s Combo of Sofosbuvir and Velpatasvir for Genotypes 1, 3 and 4

We want to hear your voice! Patient input is requested by CADTH on Gilead’s combo of sofosbuvir and velpatasvir for genotypes 1, 3 and 4.  ANYONE AFFECTED BY HEPATITIS C CAN SUBMIT; it doesn't matter which genotype you are, or if you haven't had any experience with this new treatment. Gilead’s combo is pan-genotypic (works for all genotypes).  Check out the background information below to see the results from clinical trials to date. You will see that the

Patient input is requested by BCPharmaCare for Merck’s MK2: Zepatier (grazoprevir / elbasvir)

Zepatier™ (grazoprevir / elbasvir [± ribavirin]) Merck’s combo was approved by the FDA in January: http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-fda-approval-zepatier-elbasvir-and-grazoprevi and was also approved in Canada for genotypes 1, 3 and 4 in early February: http://hepcbc.ca/2016/02/merck-receives-approval-of-zepatier-elbasvirgrazoprevir-in-canada-for-the-treatment-of-chronic-hepatitis-c-for-patients-...